Patients with stage III resected colon cancer with PIK3CA gain-of-function mutations treated with celecoxib had improved DFS, OS<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, June 27, 2024 (HealthDay News) — PIK3CA <\/em>mutational status may be beneficial for predicting response to addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant chemotherapy in stage III resected colon cancer, according to a study published online June 18 in the Journal of Clinical Oncology<\/em>.<\/p>\n Jonathan A. Nowak, M.D., Ph.D., from Brigham and Women’s Hospital in Boston, and colleagues prospectively examined whether adding the COX-2 inhibitor celecoxib to standard adjuvant chemotherapy reduces the risk of recurrence and improves survival for patients with stage III resected colon cancer. Preplanned subgroup analysis was performed by PIK3CA<\/em> mutational status. Of the 1,197 tumors with available whole-exome sequencing data, PIK3CA<\/em> gain-of-function mutations were identified in 259.<\/p>\n The researchers found that there was no significant improvement in disease-free survival (DFS) with celecoxib for all patients. On stratification by PIK3CA<\/em> status, patients with gain-of-function mutations treated with celecoxib had significantly improved DFS (adjusted hazard ratio, 0.56 [95 percent confidence interval, 0.33 to 0.96]) compared with wildtype PIK3CA<\/em> patients (adjusted hazard ratio, 0.89 [0.70 to 1.14]); the interaction was not significant. Patients with PIK3CA <\/em>gain-of-function mutations had similarly improved overall survival (adjusted hazard ratio, 0.44 [0.22 to 0.85]) compared with wildtype patients (adjusted hazard ratio, 0.94 [0.68 to 1.30]).<\/p>\n “These findings represent the first clinical trial results to validate observational studies that have associated adjuvant aspirin and other nonsteroidal anti-inflammatory drug use, including COX-2 inhibitors, with improved survival for patients with PIK3CA<\/em>-mutant colorectal cancer,” the authors write.<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n